Interim Report Quarter 1, 2026

Q1 2026 net sales fell 5.1% to SEK 33,177m, but organic sales grew 0.4% as 1.1% volume growth offset a 0.7% price/mix decline. EBITA decreased 6% to SEK 4,448m, though EBITA excluding IAC was only down 2% to SEK 4,603m, indicating relatively resilient underlying profitability. The completed acquisition of Edgewell's feminine care business in North America added 1.1% to net sales and was consolidated from February 2, 2026.

Analysis

The quality signal here is better than the headline P&L suggests: volume is inflecting while price/mix is still negative, which usually means the business is buying share in a soft end market rather than passively riding price. That matters because volume-led recovery tends to be stickier over 2-3 quarters than price-led growth, and it also implies the cost base has more operating leverage left if management can keep utilization high.

The acquired feminine-care asset is strategically useful beyond the immediate revenue lift: it likely improves category mix and North American shelf presence, but it also creates near-term integration risk exactly where margin expansion is hardest to prove. The key second-order effect is on competitors’ trade spending — if this business is taking share via promotion and distribution, peers may be forced to defend with higher allowances, which can compress category margins even if end demand is stable.

The currency drag is the main reason not to extrapolate the margin improvement too aggressively. If FX normalizes even modestly over the next 1-2 quarters, reported growth can re-accelerate without any change in underlying demand, which should help sentiment, but the inverse is also true: a stronger SEK can mask a real operating slowdown. The market is likely underestimating how much of the current setup is a translation story versus a true demand recovery, so the cleanest upside is in relative performance versus other staples/household names with weaker volume prints.

Contrarian view: the miss on reported sales may be less important than the fact that units are growing despite a weak pricing backdrop, which often precedes a broader margin reset higher once input costs lag lower and plant utilization improves. The risk is that the category remains promotional for longer, turning volume gains into a low-quality share grab. If that happens, the story shifts from earnings recovery to a balance-sheet and integration execution debate over the next 6-12 months.

Key Decisions for Investors

• Go long the stock on weakness for a 3-6 month trade if the market over-focuses on reported sales decline; target a re-rating on volume-led organic growth and FX normalization. Risk: a second quarter of negative price/mix would invalidate the margin recovery thesis.
• Pair trade: long this name / short a slower-volume, more promo-exposed consumer staples peer basket over the next 1-2 quarters. The edge is that volume inflection plus acquisition synergies should outperform pure pricing stories if category demand stays soft.
• If options are liquid, buy 3-6 month call spreads to express upside from operational leverage while capping risk around integration slippage. Best entry is after any post-print pullback, not into strength.
• Trim or hedge after a 10-15% rebound if subsequent channel checks show trade spending rising faster than volume. That would signal the growth is being bought, not earned.